According to their muscular involvement and weakness at the time of genetic counselling, the patients' impairment was classified as: mild, when only the face was affected (grade 1); moderate, when the face and upper limbs were affected (grade 2); severe, when there was major disability of the upper/lower limbs (with difficulty in raising the arms, climbing stairs, running, standing up from a chair) and musculoskeletal deformity (grade 3).
Facioscapulohumeral muscular dystrophy (FSH) is an autosomal dominant genetic condition, with onset usually in the second decade, which causes a slowly progressive muscular weakness of variable severity, affecting the face, the upper limb girdle, and eventually the lower limbs.' The estimated prevalence is approximately 1:21 0OO. 2 Padberg' estimated that 30% of FSH gene carriers are presymptomatic cases, unaware of their genetic status, as the gene has its maximum penetrance (95%) above the age of 20. 4 The recent localisation of the gene responsible for this condition at 4q355 will allow prenatal diagnosis as well as its detection before the appearance of clinical signs, leading to important psychological implications for genetic counselling. In order to adapt genetic counselling to the potential of new technologies in molecular biology, the present study was undertaken to assess for the first time the demand for genetic counselling and prediction among FSH patients focusing on three aspects: (1) the retrospective effect and effectiveness of genetic counselling, (2) the acceptance of preclinical and prenatal diagnosis, and (3) the reproductive performance of affected adults.
Subjects and methods A questionnaire containing direct questions about psychosocial aspects of genetic counselling, the interest in preclinical testing, as well as space for additional comments was sent to 46 literate FSH patients from 14 According to their muscular involvement and weakness at the time of genetic counselling, the patients' impairment was classified as: mild, when only the face was affected (grade 1); moderate, when the face and upper limbs were affected (grade 2); severe, when there was major disability of the upper/lower limbs (with difficulty in raising the arms, climbing stairs, running, standing up from a chair) and musculoskeletal deformity (grade 3).
During genetic counselling, issues such as the 50% recurrence risk for their offspring, the lack of effective treatment, and the unpredictability of the clinical course among those inheriting the FSH gene had been discussed with affected patients. The consultands were referred for physiotherapy and were advised about the importance of informing and bringing their at risk relatives to our centre.
The questions were designed to evaluate the following aspects: (1) their reaction after being informed about the diagnosis and genetic risks; (2) the impact of genetic counselling on their reproductive life; (3) their feelings regarding preclinical diagnosis and whether they felt their life would have been different had they known earlier that they carried the FSH gene; (4) their acceptance of prenatal and preclinical diagnosis; (5) their opinion about preclinical diagnosis for their young at risk children and the best age for discussion of a positive result. Deciding not to get married (2/29 = 6-9%). To seek treatment (10/29 34-5%). To prepare their child emotionally (7/29=241%). To avoid the progression of the disease (6/29= 20 7%).
To decide whether or not to have more children (2/29 = 6 9%). (8) In the case of a positive predictive result, when do you think this information should be transmitted to the children? As soon as the child can understand it (20/29 = 69 0%).
As the first symptoms appear (2/29 = 6-9%). Some would not tell their children in order to avoid suffering in advance (2/29 = 6 9%).
Before they get married (1/29 = 344%). For fitness analysis the mean number of children born to all 57 FSH patients was compared with the number of children conceived by their healthy sibs (n = 88) of comparable age. No significant difference (2 57/ 2 26= 1-137, t=0-75, p> 05) in reproductive performance was observed in FSH patients as compared to their healthy sibs. A slight difference in fitness was seen according to the gender of the patients: 2-77/2 30= 1 204 for affected males and 2-32/2 21 = 1050 for females, but it was not significant (t = 0-62 p> 005).
Discussion EFFECTIVENESS OF GENETIC COUNSELLING
Although one third of our FSH patients answered that they would have reduced the number or not have had children at all, genetic counselling had little effect on their reproductive performance because in most cases it was received relatively late (30 7 years) and almost 40% of the patients already had children at that time. As seen in table 1, the lower birth rate among female patients after genetic counselling (0-25 children per patient) in comparison with the males (0 69) can be explained by the difference in the mean age at which women (34-2 (SD 15-1) years) and men (28 8 (SD 6-4) years) were counselled.
SEVERITY OF THE PHENOTYPE
Among those who replied, the average severity of the disease in females did not differ significantly (t = 0 31, p > 0 05) from that observed in males (table 1) . There was also no difference in severity between males and females when all 57 patients were taken together (table 2) . However, males were referred for genetic counselling on average 5-4 years earlier than females. This suggests either a bias towards more severely affected or younger males, or that more middle aged affected women sought counselling and were more motivated (through having a greater concern about their children and grandchildren) to reply to the question- 15 However, HD differs from FSH in several respects, including the much lower penetrance of the HD gene in young adults, in particular during reproductive age, and the rapid and devastating progression after onset.
In the present study 25/29 (86-2%) patients showed interest in genetic testing for their children. However, the small percentage of patients (6-7%) who stated that predictive testing is important for family planning suggests that they seem to be more worried about early treatment than to prevent the birth of more affected persons in their family.
Most of our patients (27/29 = 93-1 %) did not mention aborting a pregnancy in the case of a positive test. One possible explanation might be the feeling of guilt or denial in an affected parent who aborts a child who, although handicapped, would be able to lead an almost normal life.
As the risk for FSH in an asymptomatic young adult is only 5%, it would be expected that genetic testing would be requested (1) to reassure asymptomatic young adults and children that they do not carry the defective gene; (2) to confirm or not the presence of the gene in the few cases of clinical uncertainty; (3) to offer early diagnosis in at risk children; and (4) more rarely for prenatal diagnosis.
FITNESS IN FSH PATIENTS
In accordance with previous investigations3 16 no reduction of reproductive performance was observed among our FSH patients (f= 1 137), in contrast to our limb-girdle muscular dystrophy (LGMD) families where we found a much lower fitness in females (0 45) than in males (098). '7 It will be interesting to confirm, through personal interviews, the wish for taking predictive testing (both preclinical and prenatal) and its influence on reproductive performance in our young FSH patients, as well as comparing such results with observations from other populations. A similar study for myotonic dystrophy, whose gene has recently been identified,'8 will be of great interest.
